Moodnet Research Group, Haukeland University Hospital, Bergen, Norway.
J Clin Psychopharmacol. 2011 Dec;31(6):734-9. doi: 10.1097/JCP.0b013e318235f4e9.
Clinical, epidemiological, and, recently, genome-wide linkage and genome-wide association studies suggest migraine and bipolar disorder are comorbid phenomena. The objective of this study was to determine whether there is also evidence that this comorbidity exists by virtue of there being a positive relationship between the prescription of medications used to treat migraine and mood-stabilizing agents using the National Norwegian Prescription Database.
Data allowing ascertainment of the concurrence of prescriptions for migraine and mood-stabilizing agents were gleaned from the Norwegian Prescription Database for calendar year 2006, covering the total population (N = 4,640,219). Results were obtained using logistic regression analyses and were expressed by odds ratios (ORs).
A total of 81,225 persons (1.8% of the population) received medications for migraine and 19,517 (0.45%) received a mood-stabilizing agent for a bipolar disorder; 843 persons received both types of medications. The OR expressing the relationship between the concurrent use of both categories of medications was 2.55 (95% confidence interval [CI], 2.38-2.73, P < 0.001, z score = 26.44), significant for all mood stabilizers (lithium: OR = 1.82 [95% CI, 1.58-2.10], P < 0.001, z score = 8.31; carbamazepine: OR = 2.48 [95% CI, 2.01-3.06], P < 0.001, z score = 8.42; valproic acid: OR = 2.26 [95% CI, 1.89-2.70], P < 0.001, z score = 8.96; and lamotrigine: OR = 3.50 [95% CI, 3.14-3.90], P < 0.001, z score = 22.68). The association was significantly higher for men (OR = 3.16 [95% CI, 2.74-3.66], P < 0.001, z score = 15.53) than for women (OR = 2.21 [95% CI, 2.04-2.39], P < 0.001, z score = 19.61) and was most pronounced in younger age groups and for lamotrigine.
There was a strong positive association between the prescription of medications used to treat migraine and mood-stabilizing agents. This is compatible with the hypothesis that migraine and bipolar disorders are associated with one another.
临床、流行病学，以及最近的全基因组连锁和全基因组关联研究表明，偏头痛和双相情感障碍是共病现象。本研究的目的是通过利用挪威全国处方数据库来确定是否有证据表明这种共病存在，即治疗偏头痛的药物和稳定情绪的药物之间存在正相关关系。
从挪威处方数据库中获取了 2006 年偏头痛和稳定情绪药物处方并存的相关数据，涵盖了总人口（N=4640219 人）。使用逻辑回归分析得到结果，并以比值比（OR）表示。
共有 81225 人（占总人口的 1.8%）接受了偏头痛药物治疗，19517 人（占 0.45%）接受了双相情感障碍的稳定情绪药物治疗；843 人同时接受了这两种类型的药物治疗。同时使用这两类药物的关系的 OR 为 2.55（95%置信区间[CI]，2.38-2.73，P<0.001，z 分数=26.44），所有稳定情绪药物均有统计学意义（锂：OR=1.82[95%CI，1.58-2.10]，P<0.001，z 分数=8.31；卡马西平：OR=2.48[95%CI，2.01-3.06]，P<0.001，z 分数=8.42；丙戊酸：OR=2.26[95%CI，1.89-2.70]，P<0.001，z 分数=8.96；拉莫三嗪：OR=3.50[95%CI，3.14-3.90]，P<0.001，z 分数=22.68）。男性（OR=3.16[95%CI，2.74-3.66]，P<0.001，z 分数=15.53）的关联明显高于女性（OR=2.21[95%CI，2.04-2.39]，P<0.001，z 分数=19.61），且在年轻人群和拉莫三嗪中更为显著。
治疗偏头痛的药物和稳定情绪的药物之间存在强烈的正相关关系。这与偏头痛和双相情感障碍之间存在关联的假设是一致的。
